OncoMatch/Clinical Trials/NCT06798363

Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma

Is NCT06798363 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies propranolol for infantile hemangioma.

Phase 2/3RecruitingWest China HospitalNCT06798363Data as of Jun 2026Location: China

Treatment: propranolol — The main objective of this study was to determine the efficacy of different doses of propranolol in the treatment of ulcerattion infantile hemangioma (IH).

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

propranolol

Demographics

Ages 0–4

Prior therapy

Cannot have received: other therapeutic interventions

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06798363 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior other therapeutic interventions disqualifies patients from enrollment.

Is there an age limit?

Yes. Patients must be 4 years or younger and at least 0 years old.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify